FindTrial
Sign In

Fundamental Research on Perioperative Immune Regulation to Prevent Postoperative Recurrance of Rectal Cancer

Fundamental Research on Perioperative Immune Regulation to Prevent Postoperative Recurrance of Rectal Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-10000866
Enrollment
Unknown
Registered
2010-05-18
Start date
2011-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rectal cancer

Interventions

Group A:Oral administration of celecoxib for 5 days before operation
Group B:Oral administration of celecoxib for 5 days before operation

Sponsors

Center of Gastroenterology, West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who were diagnosed as rectal cancer by enteroscope biopsy.

Exclusion criteria

Exclusion criteria: Patients with acute inflammation,infection, intestinal obstruction, intestinal perforation, fever and recurrant cancer.

Design outcomes

Primary

MeasureTime frame
CRP, IL-6, COX-2, short-term and long-term prognose;—

Countries

China

Contacts

Public ContactLI LI
lockwan@qq.com+86 028 89069251

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026